You are here
Generic Form of Duragesic Granted Final Approval
January 31, 2005
PITTSBURGH, Jan. 28 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE:MYL) today announced that the U.S. Food and Drug Administration has granted final approval for Mylan Technologies' Abbreviated New Drug Application for Fentanyl Transdermal System in 25 mcg/hr, 50 mcg/hr, 75 mcg/hr and 100 mcg/hr strengths. Fentanyl is the generic version of Alza Corporation's Duragesic.
The product will be shipped immediately.
Source: Mylan Laboratories, Inc.
Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients
Zip Device Faster to Apply, Minimizes Scarring
May Solve Two Problems at Once
Statistically Significant Improvement in Excessive Daytime Sleepiness
Researcher Made Himself Guinea Pig to Test the Drug
Treatment Shorter, Less Complicated Than Typical Regimen